AbbVie (NYSE: ABBV) today announced positive top-line results from the Phase 3 SELECT-BEYOND clinical trial evaluating upadacitinib (ABT-494), an investigational ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Management Comments

Near-Term Bullish Options Activity in AbbVie (ABBV) Targets Upside Above $90 Amid Rally in Shares -SusuqehannaSeptember 13, 2017 1:55 PM Speculative Bullish Options Flow in AbbVie (ABBV) as Management Presents at Healthcare Conference -Susquehanna September 12, 2017 2:33 PM AbbVie's Upadacitinib (ABT-494) Meets All Primary and Ranked Secondary Endpoints in Second Phase 3 Study in Rheumatoid ArthritisSeptember 11, 2017 8:02 AM Abbvie (ABBV): IPR Victory Translates Into A 36% PT Increase - CowenSeptember 11, 2017 6:16 AM AbbVie (ABBV) Declares $0.64 Quarterly Dividend; 3.1% YieldSeptember 8, 2017 11:04 AM Abbvie (ABBV) PT Raised to $100 at Goldman SachsSeptember 8, 2017 4:17 AM Jefferies Reiterates Bullish View on Abbvie (ABBV) Amid 'Double Dose' of Good NewsSeptember 7, 2017 1:06 PM Coherus BioSciences (CHRS) 'Disappointed' in Outcome of '619 IPR Institution DecisionSeptember 7, 2017 11:59 AM AbbVie (ABBV) Trades at Session High as Biotech Strength Continues, IPR Review VictorySeptember 7, 2017 11:45 AM AbbVie (ABBV) Says Upadacitinib Met Primary Endpoint in Phase 2b Study in Atopic DermatitisSeptember 7, 2017 8:05 AM Wall St. ends flat as media stocks slump, healthcare gainsSeptember 7, 2017 7:39 AM